| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6100037 | Journal of Crohn's and Colitis | 2012 | 8 Pages |
Abstract
Clinical response to adalimumab therapy is associated with an improvement in linear growth in a proportion of children with CD. Improved growth is more likely in patients entering remission and on immunosuppression but is not solely due to a steroid sparing effect.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
S. Malik, S.F. Ahmed, M.L. Wilson, N. Shah, S. Loganathan, S. Naik, B. Bourke, A. Thomas, A.K. Akobeng, A. Fagbemi, D.C. Wilson, R.K. Russell,